Summary
Based on mechanistic understandings, molecular modeling and extensive quantitative structure-activity relationships, appropriately substituted haloallylamine derivatives were designed as potential mechanism-based inhibitors of MAO and/or SSAO. Potent inhibition of MAO-B and SSAO occurred with fluoroallylamines whereas chloroallylamines, such as MDL 72274A ((E)-2-phenyl-3-chloroallylamine hydrochloride), were selective and potent inhibitors of SSAO. MDL 72974A (E)-2-(4-fluoroph-enethyl)-3-fluoroallylamine hydrochloride is a potent (IC50 = 10-9M) inhibitor of both MAO-B and SSAO, with 190-fold lower affinity for MAO-A. In clinical studies, oral doses as low as 100μg produced substantial inhibition of platelet MAO-B. Essentially complete inhibition occurred at 1 mg with the effect lasting 6–10 days. One or 4 mg MDL 72974A given daily for 28 days to 40 Parkinson’s patients treated with L-dopa produced statistically significant reductions in the Unified Parkinson’s Disease Rating Scale. MAO-B inhibitors, such as MDL 72974A and L-deprenyl, offer the potential of being neuroprotective in Parkinson’s Disease and other neurogenerative disorders. Concommitant inhibition of SSAO may provide additional, but as yet unproven, advantages over pure inhibitors of MAO-B.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Aasly J, Green D, Hardenberg J, Harland D, Huebert N, Myllvla V, Rinne U, Seppala A, Sjaastad, Sotaniemi K (1991) An open multicenter study of the efficacy of MDL 72974A in Parkinson’s disease when administered at a daily dose of 1 or 4mg for 4 weeks as adjuvant therapy to L-DOPA. Proceedings, 10th International Symposium on Parkinson’s Disease, Tokyo, Japan.
Alken RG, Palfreyman MG, Brown MJ, Davies DS, Lewis PJ, Schechter PJ (1984) Selective inhibition of MAO type B in normal volunteers by MDL 72145. Br J Pharmacol 17: 615–616P.
Bey P, Fozard J, Lacoste JM, McDonald IA, Zreika M, Palfreyman MG (1984) (E)-2-(3,4-Dimethoxy)-3-fluoroallylamine: a selective, enzyme activated inhibitor of type B monoamine oxidase. J Med Chem 27: 9–10.
Fozard JR, Zreika M, Robin M, Palfreyman MG (1985) The functional consequences of inhibition of monoamine oxidase type B; comparison of the pharmacological properties of L-deprenyl and MDL 72145. Naunyn Schmiedebergs Arch Pharmacol 331: 186–193.
Harland D, Seppala A, Hinze C, Hardenberg J, Zreika M (1990) A double-blind placebo-controlled study of the tolerability and effects on platelet MAO-B activity of single oral doses of MDL 72974A in normal volunteers. Eur J Pharmacol 183: 530.
Hinze C, Harland D, Zreika M, Dulery B, Hardenberg J (1990) A double-blind, placebo-controlled study of the tolerability and effects on platelet MAO-B activity of single oral doses of MDL 72974A in normal volunteers. J Neural Transm [Suppl] 32: 203–209.
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442.
Lyles GA, Marshall CMS, McDonald IA, Bey P, Palfreyman MG (1987) Inhibition of rat aorta semicarbazide-sensitive amine oxidase by 2-phenyl-3-haloallylamines and related compounds. Biochem Pharmacol 36: 2847–2853.
McDonald IA, Lacoste J-M, Bey P, Palfreyman MG, Zreika M (1985) Enzyme activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships. J Med Chem 28: 186–193.
McDonald IA, Palfreyman MG, Zreika M, Bey P (1986) (Z)-2-(2,4-Dichlorophenoxy) methyl-3-fluoroallylamine (MDL 72638): a clorgyline analogue with surprising selectivity for monoamine oxidase type B. Biochem Pharmacol 35: 349–351.
McDonald IA, Bey P, Zreika M, Palfreyman MG (1991) MDL 72974A: monoamine oxidase type B inhibitor, antiparkinson. Drugs of the Future 16 5: 428–431.
Nicklas WJ, Terleckyj T (1992) Pharmacological aspects of chronic MAO-B inhibitor administration to rodents. 15th Annual Scientific Meeting of the Canadian College of Neuropsychopharmacology, Saskatoon (poster T-11).
Palfreyman MG, Zreika M, McDonald IA, Fozard J, Bey P (1984) MDL 72145, an irreversible inhibitor of MAO-B. In: Tipton KF, Dostert P, Strolin-Benedetti (eds) Monoamine oxidase and disease. Academic Press, London, pp 563–564.
Palfreyman MG, McDonald IA, Bey, P, Danzin C, Zreika M, Lyles GA, Fozard JR (1986) The rational design of suicide substrates of amine oxidases. Biochem Soci Transact 14: 410–413.
Palfreyman MG, McDonald IA, Zreika M, Dudley M, Bey P (1991) Potent and selective irreversible inhibition of MAO-B by MDL 72974A. Eur Neuropsycho-pharmacol 1: 319–321.
Palfreyman MG, McDonald IA, Zreika M, Cremer G, Haegele K, Bey P (1993) MDL 72974A: a selective MAO-B inhibitor with potential for treatment of Parkinson’s disease. J Neural Transm (in press).
Rando RR (1973) 3-Bromoallylamine induced irreversible inhibition of monoamine oxidase. J Am Chem Soc 95: 4438–4439.
Rando RR, Eigner A (1977) The pseudoirreversible inhibition of monoamine oxidase by allylamine. Mol Pharmacol 13: 1005–1013.
Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666–672.
Walsh CT (1984) Suicide substrates, mechanism-based enzyme inactivators: recent developments. Ann Rev Biochem 53: 493–535.
Yu PH, Zuo DM (1992) Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species. Biochem Pharmacol 43: 307–312.
Zreika M, McDonald IA, Bey P, Palfreyman MG (1984) MDL 72145, an enzyme activated irreversible inhibitor with selectivity for monoamine oxidase type B. J Neurochem 43: 448–454.
Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG (1989) MDL 72974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson’s disease. J Neural Transm [P-D sect] 1: 243–254.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag
About this paper
Cite this paper
Palfreyman, M.G., McDonald, I.A., Bey, P., Danzin, C., Zreika, M., Cremer, G. (1994). Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential. In: Tipton, K.F., Youdim, M.B.H., Barwell, C.J., Callingham, B.A., Lyles, G.A. (eds) Amine Oxidases: Function and Dysfunction. Journal of Neural Transmission, vol 41. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9324-2_54
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9324-2_54
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82521-1
Online ISBN: 978-3-7091-9324-2
eBook Packages: Springer Book Archive